Clinical Trials Logo

Filter by:
NCT ID: NCT04642612 Terminated - Regional Anesthesia Clinical Trials

Cerebral Blood Flow Evaluation With Trancranial Doppler After Interscalene Nerve Block

CBF-TCD
Start date: March 4, 2021
Phase:
Study type: Observational

The purpose of this study is to assess cerebral blood flow velocity (CBFV) following regional anesthesia for shoulder surgery. The results of this study will help to further understand the physiologic effect of the interscalene nerve block on cerebral blood flow.

NCT ID: NCT04641962 Terminated - Clinical trials for Primary Mitochondrial Myopathy

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

MOUNTAINSIDE
Start date: May 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose response of ASP0367 on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.

NCT ID: NCT04641598 Terminated - Fertility Disorders Clinical Trials

Menstrual Phase Endometrial Scratch in IUI Cycles

Start date: August 31, 2018
Phase: N/A
Study type: Interventional

Patients undergoing treatment with intrauterine insemination (IUI) will be randomized to receive an endometrial scratch or sham procedure during the menstrual phase of the treatment cycle.

NCT ID: NCT04639947 Terminated - Glaucoma Clinical Trials

Reliability and Reproducibility of the Eye Check Tonometer

EyeCheck
Start date: January 6, 2021
Phase: N/A
Study type: Interventional

To investigate whether the new applanation tonometer (EyeCheck monitor) can provide intraocular pressure (IOP) measurements comparable to those of traditional tonometers such as the Goldmann applanation tonometer and the Tonopen.

NCT ID: NCT04639310 Terminated - Epilepsy Clinical Trials

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

EPIK
Start date: March 29, 2021
Phase: Phase 3
Study type: Interventional

To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

NCT ID: NCT04639258 Terminated - Clinical trials for Aortic Valve Stenosis

Medtronic Evolutâ„¢ EXPAND TAVR I Feasibility Study

Start date: May 28, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to obtain safety and effectiveness data of the Medtronic Evolutâ„¢ PRO+ TAVR System for the treatment of severe, asymptomatic aortic stenosis.

NCT ID: NCT04639245 Terminated - Clinical trials for Metastatic Malignant Solid Neoplasm

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Start date: July 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial investigates the side effects of genetically engineered cells called FH-MagIC TCR-T cells and how well they work with atezolizumab in treating patients with triple negative breast cancer, urothelial cancer, or non-small cell lung cancer that has spread to other places in the body (metastatic). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize MAGE-A1, a protein on the surface of tumor cells. These MAGE-A1-specific T cells may help the body's immune system identify and kill MAGE-A1 tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FH-MagIC TCR-T cells with atezolizumab may help treat patients with triple negative breast cancer, urothelial cancer, or non-small cell lung cancer.

NCT ID: NCT04639024 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug. Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy. There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.

NCT ID: NCT04638400 Terminated - Inflammation Clinical Trials

Anti-inflammatory Effects of Simvastatin

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine which of the two ingredients of Vytorin (Simvastatin or Ezetimibe) is responsible for the anti-inflammatory effects of Vytorin

NCT ID: NCT04638387 Terminated - Clinical trials for Osteoarthritis, Knee

PB125, Osteoarthritis, Pain, Mobility, and Energetics

Start date: November 3, 2020
Phase: N/A
Study type: Interventional

Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important regulator in the body. It controls how well cells protect themselves against stress. PB125 (Pathways Bioscience) is a plant based activator of this important regulator Nrf2. PB125 is made up of three plant extracts (rosemary, ashwagandha, and Sophora japonica) so that it contains these things; 1. Carnosol, 2. Withaferin A, and 3. Luteolin. Carnosol comes from rosemary leaves. Rosemary is a spice often used in Italian foods and grown in many herb gardens all around Fort Collins. Withaferin A comes from the medicinal plant Withania somnifera, also called ashwagandha. Ashwaganda is commonly known as "Indian Winter cherry" or "Indian Ginseng" and it is one of the most important herbs of Ayurveda (the traditional system of medicine in India) used for millennia. Finally, luteolin is found widely in plants including those present in the diet (peppers, onions, celery, herbs/spices). Some people purchase these herbs commercially, and take them on their own for a variety of purposes. Typically, when you buy them, they will be in much higher doses than they are in PB125. What makes PB125 different is that very low doses of each of the 3 components work together-synergistically-to activate Nrf2 and increase the ability of cells to respond to stress. It is unknown if there are any benefits to taking PB125 and the risks are currently unknown. The purpose of this study is to examine changes in muscle, in joint pain, in mobility (standing and walking) and in leg strength that occur after consuming PB125 every day for 3 months. We want to make these measurements in people who have been diagnosed with mild to moderate osteoarthritis-a degenerative joint disease-in their knees.